Table 2 Comparison of development of CFT and BCVA of the Ranibizumab and the Aflibercept group after the loading dose and after 1 year, respectively
Ranibizumab (16 eyes) | Aflibercept (11 eyes) | Difference | Confidence interval | p-value | |
|---|---|---|---|---|---|
Loading phase | |||||
Change of Letters after loading dose(mean ± SD) | 13.81 ± 20.48 | 6.36 ± 15.46 | 7.45 | −7.58 to 22.48 | 0.317 |
Change of CFT after loading dose (mean ± SD) [μm] | −169.06 ± 140.60 | −84.73 ± 143.65 | −84.34 | −198.74 to 30.07 | 0.142 |
1 year | |||||
Change of Letters after 1 year (mean ± SD) | 15.00 ± 21.77 | 5.64 ± 12.64 | 9.36 | −5.69 to 24.41 | 0.212 |
Change of CFT after 1 year (mean ± SD) [μm] | −155.50 ± 160.14 | 78.45 ± 165.83 | −77.05 | −208.08 to 53.99 | 0.237 |